The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib

Gioacchino Catania, Rita Tavarozzi, Giacomo Maria Pini, Tiziana Borra, Carolina Gandolfo, Giulia Zacchi, Daniela Pietrasanta, Federico Monaco, Manuela Zanni, Maddalena Lettieri, Paolo Rivela, Francesco Zallio, Marco LADETTO

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic leukemia (a-CLL) is a relatively rare form of CLL representing less than 1 % of all CLL cases. a-CLL patients usually have a more aggressive course and a reduced overall survival was reported with conventional chemo-immunotherapy approaches. Methods: The role of Bruton Tyrosine Kinase-inhibitor, ibrutinib, in a-CLL is well established with encouraging preliminary results. Results: We report a case of a-CLL-treated first-line with second-generation BTKi, acalabrutinib with a prompt clinical response. As known, it is the first literature report on acalabrutinib in a-CLL highlighting the role of second-generation BTKi also in this high-risk setting. Conclusions: Target therapies (Bruton Kinase inhibitors and Bcl2 inhibitors) have improved the therapeutic landscape of CLL. The availability of therapeutic targets requires greater diagnostic accuracy to choose the most appropriate therapy for each patient.
Lingua originaleInglese
pagine (da-a)401-404
Numero di pagine4
RivistaJournal of Basic and Clinical Physiology and Pharmacology
Volume34
Numero di pubblicazione3
DOI
Stato di pubblicazionePubblicato - 2023

Keywords

  • Bruton kinase inhibitors
  • leukemia
  • precision medicine
  • target therapy

Fingerprint

Entra nei temi di ricerca di 'The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib'. Insieme formano una fingerprint unica.

Cita questo